Business Context and Reporting Period
Kamada Ltd. filed this Form 6-K on May 14, 2015, for the month of May 2015. The filing serves as a report of a foreign private issuer and is incorporated by reference into the company's Form S-8 Registration Statement.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or liquidity metrics. The primary financial disclosure concerns the company's Series C Debentures:
- Interest Rate: 1.56322% for the period from March 1, 2015, to May 31, 2015.
- Annualized Rate: 6.25288%.
- Payment Date: June 1, 2015.
- Record Date: May 20, 2015.
- Ex-Date: May 20, 2015.
Material Changes
The filing does not provide comparative financial data or material changes in operating results versus prior periods. It solely announces the specific interest rate applicable to the current quarter for the Series C Debentures.
Guidance, Outlook, and Risks
The filing includes a cautionary note regarding forward-looking statements. Management highlights that actual results may differ materially from expectations due to several risks, including:
- Unexpected results of clinical trials.
- Delays or denial of approval by the U.S. FDA or the European Medicines Agency (EMA).
- Additional competition in the Alpha-1 Antitrypsin Deficiency (AATD) market.
- Further regulatory delays.
The company states it undertakes no obligation to update these forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the record date of May 20, 2015, to confirm eligibility for the upcoming interest payment.
- Confirm the payment date of June 1, 2015, for the Series C Debentures.
- Review the annualized interest rate of 6.25288% against current market rates for similar debt instruments.
- Monitor upcoming clinical trial results and regulatory filings with the FDA and EMA, as these are cited as primary risks to future performance.